Skip to main content
. 2021 Sep 24;65(3):108–114. doi: 10.3345/cep.2020.01984

Table 2.

Japanese encephalitis vaccines licensed for use in Korea

Type of vaccine Manufacturer Trade name Virus strain Substrate Immunization schedule
JE-MBa) Greencross Greencross Japanese encephalitis vaccine Nakayama Mouse brain Days 0, 7–30 at 12–23 months of age; booster after 1 year, then 6, 12 years of age
Boryung Biopharma Boryung Japanese encephalitis vaccine
Boryung Japanese encephalitis vaccine PFS
JE-VC Boryung Biopharma Boryung cell-culture Japanese encephalitis vaccine Beijing-1 Vero cells
Greencross cell-culture Japanese encephalitis vaccine
LJEV Glovax CD.JEVAX SA-14-14-2 PHK cells 1st dose at 12–23 months of age; 2nd dose 12 months after 1st dose
JE-CV Sanofi Pasteur IMOJEV SA14-14-2/yellow fever 17D Vero cells

JE-CV, recombinant chimeric virus vaccine; JE-MB, inactivated Japanese encephalitis vaccine; JE-VC, inactivated Vero cell-derived Japanese encephalitis vaccine; LJEV, live-attenuated Japanese encephalitis vaccine; PHK, primary hamster kidney.

a)

JE-MB is not currently in use and has been replaced by JE-VC.

Adapted from the Korean Pediatric Society. Japanese encephalitis vaccines. In: Kim JH, editor. Immunization guideline. 9th ed. [16]